MyBCTeam

Those are really important questions, especially when weighing treatment decisions after completing primary therapy.

For stage 2A TNBC specifically, research shows that roughly 20 percent of people with early-stage TNBC (stages 1 and 2A) experience a recurrence. This is notably lower than the 40 percent recurrence rate Show Full Answer

Those are really important questions, especially when weighing treatment decisions after completing primary therapy.

For stage 2A TNBC specifically, research shows that roughly 20 percent of people with early-stage TNBC (stages 1 and 2A) experience a recurrence. This is notably lower than the 40 percent recurrence rate seen in stages 2B and 3.

Factors that can influence recurrence risk include:

- Lymph node involvement
- Tumor size
- Age at diagnosis (younger than 35 carries higher risk)
- Whether surgery achieved clear margins
- BMI in the obesity range (30 or higher)

Having a residual cancer burden (RCB-II) after neoadjuvant chemotherapy does indicate some remaining cancer activity, which can raise recurrence concern — but it's not the same as having a poor response overall. Regarding capecitabine, it's commonly used after surgery for TNBC patients who had residual disease (like RCB-II). Studies have shown it can meaningfully reduce recurrence risk in this group, which is why oncologists often recommend it despite its side effects.

Whether the side effects are "worth it" is deeply personal and depends on your overall health and tolerance. That conversation is best had with your oncologist, who can weigh your specific situation. Many MyBCTeam members have navigated this exact decision — you're definitely not alone in asking it.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Triple-Negative Breast Cancer Recurrence Rate: 8 Facts To Know

Triple-Negative Breast Cancer Stage 2: What To Expect